Rocket Pharmaceuticals, Inc. financial data

Symbol
RCKT, RCKTW on Nasdaq
Location
350 Fifth Avenue, Suite 7530, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 766 % -20.1%
Debt-to-equity 16.3 % +20.7%
Return On Equity -66 % -21.2%
Return On Assets -56.8 % -18.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 108M shares +18.6%
Common Stock, Shares, Outstanding 108M shares +18.6%
Entity Public Float 1.4B USD +16.7%
Common Stock, Value, Issued 1.08M USD +18.6%
Weighted Average Number of Shares Outstanding, Basic 111M shares +18.4%
Weighted Average Number of Shares Outstanding, Diluted 111M shares +18.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 158M USD -12.1%
General and Administrative Expense 106M USD +18.2%
Operating Income (Loss) -268M USD +0.79%
Net Income (Loss) Attributable to Parent -257M USD -1.6%
Earnings Per Share, Basic -2 USD/shares +9.39%
Earnings Per Share, Diluted -2 USD/shares +9.39%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 32.8M USD -15%
Cash, Cash Equivalents, and Short-term Investments 272M USD -2.62%
Assets, Current 277M USD -5.32%
Property, Plant and Equipment, Net 32.5M USD -17.8%
Operating Lease, Right-of-Use Asset 3.83M USD -15.8%
Intangible Assets, Net (Excluding Goodwill) 25.2M USD 0%
Goodwill 39.2M USD 0%
Assets 421M USD -5.7%
Employee-related Liabilities, Current 8.05M USD +10.4%
Liabilities, Current 43.4M USD +15.4%
Operating Lease, Liability, Noncurrent 2.93M USD -17.9%
Other Liabilities, Noncurrent 1.06M USD -14.8%
Liabilities 66.8M USD +8.08%
Accumulated Other Comprehensive Income (Loss), Net of Tax -107K USD +50.9%
Retained Earnings (Accumulated Deficit) -1.35B USD -23.6%
Stockholders' Equity Attributable to Parent 354M USD -7.91%
Liabilities and Equity 421M USD -5.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.8M USD +1.88%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -58M USD -266%
Common Stock, Shares Authorized 180M shares 0%
Common Stock, Shares, Issued 108M shares +18.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 34.2M USD -14.5%
Deferred Tax Assets, Valuation Allowance 129M USD +19%
Operating Lease, Liability 3.94M USD -14.4%
Payments to Acquire Property, Plant, and Equipment 364K USD -82.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -257M USD -1.76%
Lessee, Operating Lease, Liability, to be Paid 5.21M USD -16.6%
Property, Plant and Equipment, Gross 58.3M USD +2%
Operating Lease, Liability, Current 1.01M USD -2.23%
Lessee, Operating Lease, Liability, to be Paid, Year Two 759K USD -24.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.01M USD +0.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.27M USD -22.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 522K USD -31.2%
Deferred Tax Assets, Operating Loss Carryforwards 67.6M USD +49.2%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 539K USD +3.26%
Operating Lease, Payments 364K USD +9.31%
Additional Paid in Capital 1.7B USD +15.4%
Depreciation, Depletion and Amortization 7.5M USD +36.4%
Share-based Payment Arrangement, Expense 43.5M USD +4.05%
Interest Expense 1.89M USD +0.43%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%